Ratings UFP Technologies, Inc.

Equities

UFPT

US9026731029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
213.2 ^USD	+1.72%		+2.56%	+23.95%

Mar. 20	CJS Securities Initiates UFP Technologies With Market Outperform Rating, $255 Price Target	MT
Mar. 05	North American Morning Briefing : S&P 500 Futures -2-	DJ

Strengths

Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.96 times its estimated earnings per share for the ongoing year.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
UFP TECHNOLOGIES, INC.	+23.95%	1.63B	C
ABBOTT LABORATORIES	-2.31%	187B	C+
MEDTRONIC PLC	-3.20%	106B	C
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B	A
DEXCOM, INC.	+0.20%	49.45B	B-
CENCORA, INC.	+17.29%	48B	B-
HOYA CORPORATION	+4.06%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B	A-
TERUMO CORPORATION	+12.96%	24.62B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes